Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Dateline City:
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, an orally available kinase inhibitor discovered by Eisai. The primary endpoint was objective response rate (ORR) at week 24 as assessed by investigators per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).
Language:
English
Contact:
Merck Media Relations
Pamela Eisele: (267) 305-3558
Kristen Drake: (908) 334-4688
Merck Investor Relations
Courtney Ronaldo: (908) 740-6132
Eisai Inc. Media Relations
Michele Randazzo: (201) 746-2979
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck